Parkinson's research is evolving, with a dramatic increase in patient involvement, advanced systems of measurement, and real-world data gathering at the forefront. Subjective assessments and endpoints can now be augmented with richer data sources gathered directly via wearables, sensors, and mobile technology. Beyond enabling data collection outside the clinic, these models, tied to existing gold standard measurements, enhance all stakeholders' abilities to access more sensitive, frequent, and objective measures of Parkinson’s progression.
The COVID-19 pandemic was an impetus for industry-wide digital endpoint validation already underway in Parkinson's research. Learn from two experts at the forefront of this research, Josh Cosman PhD , Director of Digital Health Strategy at Abbvie, and David Anderson PhD, Senior Scientist at Clinical ink, as they discuss the Parkinson's patient experience. They will address why digital transformation is well-positioned in this therapeutic area, and how validating WATCH-PD decentralized study design, BrainBaselineTM technology, and digital endpoints serve as a harbinger for Parkinson's and movement disorders research, as well as clinical discovery at large.
This webinar will be a dynamic conversation revealing challenges in traditional Parkinson's study models, the power of expertly engineered technologies, data capture, and analytic methods, and opportunities for growth direct from patients, sponsors, sites, and the broader Parkinson's research community.
KEY LEARNING OBJECTIVES:
- Current landscape of Parkinson’s clinical trials
- A historical perspective of the Parkinson’s patient experience
- How wearables, sensors and remote trials are augmenting Parkinson’s clinical trials and providing new, richer data sources
- Opportunities for further digital growth for Parkinson’s disease research